share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Atkinson Edward Morrow III

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Atkinson Edward Morrow III

福泰製藥 | 4：持股變動聲明-高管 Atkinson Edward Morrow III
美股sec公告 ·  05/17 04:20
牛牛AI助理已提取核心訊息
Edward Morrow III, EVP and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (VRTX), was granted 14,112 shares of common stock on May 14, 2024. The transaction, which was completed on the same date, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Morrow's direct holdings in the company increased to a total of 30,084 shares of common stock.
Edward Morrow III, EVP and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (VRTX), was granted 14,112 shares of common stock on May 14, 2024. The transaction, which was completed on the same date, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Morrow's direct holdings in the company increased to a total of 30,084 shares of common stock.
2024年5月14日，Vertex Pharmicals Inc.（VRTX）執行副總裁兼首席技術運營官愛德華·莫羅三世獲得了14,112股普通股。該交易於同日完成，是一筆贈款，交易價格爲每股0.00美元，這表明這些股票可能是作爲薪酬待遇或激勵計劃的一部分授予的。在這筆交易之後，莫羅在該公司的直接持股量增加到總共30,084股普通股。
2024年5月14日，Vertex Pharmicals Inc.（VRTX）執行副總裁兼首席技術運營官愛德華·莫羅三世獲得了14,112股普通股。該交易於同日完成，是一筆贈款，交易價格爲每股0.00美元，這表明這些股票可能是作爲薪酬待遇或激勵計劃的一部分授予的。在這筆交易之後，莫羅在該公司的直接持股量增加到總共30,084股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。